Rejection expected and $5.39-6.20 range consistent

Research evidence excerpt

Rejection expected and $5.39-6.20 range consistent

le to select stocks in Asia/Australia/NZ

12-month target – Expected share price *equivalent fully paid ordinary weighted average number of

in 12 months Note: expected return is reflective of a Medium Volatility shares

Valuation – The company's estimated stock and should be assumed to adjust proportionately

All Reported numbers for Australian/NZ listed stocks are fair value share price based on the disclosed with volatility risk

modelled under IFRS (International Financial Reporting valuation methodology

Standards). Note: Quant recommendations may differ

from Fundamental Analyst recommendations

Recommendation proportions for quarter ending 31 Mar 2026

AU/NZ Asia USA

Outperform 66.90% 69.32% 67.14% (for global coverage by Macquarie, 1.93% of stocks followed are investment banking clients)

Neutral 27.18% 17.21% 32.86% (for global coverage by Macquarie, 0.40% of stocks followed are investment banking clients)

Underperform 5.92% 13.47% 0.00% (for global coverage by Macquarie, 0.00% of stocks followed are investment banking clients)

Company-Specific Disclosures

Company Name Disclosure

Atlas Arteria (ALX AU) Macquarie Group Limited together with its affiliates owns a net long of 0.5% or more of the equity securities of Atlas Arteria

Outperform Group.

12-month target: AUD5.02 - DCF Macquarie Group Limited together with its affiliates beneficially owns 1% or more of the equity securities of Atlas Arteria Group.

Valuation: AUD 4.74 - DCF (WACC 7.5%,

beta 1.0, ERP 5.0%, RFR 2.5%)

Price: AUD4.84

Target Price Risk Disclosures

Company Name Risk Disclosure

ALX faces a major immediate risk of increase in concession taxes around APRR, which would affect both the cash flow for Atlas Arteria (ALX AU) •

dividends and valuation.